BioWorld Asia

April 30, 2003

Diatos Licenses European Rights To Cancer Drug From Medarex

PARIS - Diatos SA and Medarex Inc. signed a licensing agreement giving Diatos exclusive European rights to develop and commercialize a potential new cancer treatment. (BioWorld International) Read More

Biotech Groups In Norway Unite, Plan To Catch Up With Neighbors

Genetic Study Of Clotting Enzyme Points To 'Fantastic' Drug Target

Curnock Cook Investing Again After Forming New €150M Fund

No Abstract Read More

PPL Gives Up Plans On Plant To Manufacture AAT Product

French Companies, Agency Unite For Effort In America

Alizyme Eyes Phase III, Alliance Following Renzapride Results

GenoWay Raises EUR3.3M To Fund Work On Animal, In Vitro Models

Merck Stops Development Of Celltech PDE-4 Inhibitor

UK Industry Gathers To Celebrate 50th Anniversary Of DNA Finding

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for July 24, 2026.

To viral or not to viral: In vivo CAR T debates delivery tech

BioWorld

The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 21, 2026

Tree in the shape of human head losing leaves

KBN-2201 reverses key features of Alzheimer’s in mice

BioWorld Science

Researchers from Ajou University School of Medicine reported the preclinical efficacy of KBN-2201 in a mouse model of late-stage Alzheimer’s disease.

To viral or not to viral: In vivo CAR T debates delivery tech

BioWorld Science

The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...